1. Imidazopyridyl compounds as aldosterone synthase inhibitors
- Author
-
Brent R. Whitehead, Michael M.-C. Lo, Amjad Ali, Min K. Park, Scott B. Hoyt, Yusheng Xiong, Jiaqiang Cai, Emma Carswell, Andrew Cooke, John MacLean, Paul Ratcliffe, John Robinson, D. Jonathan Bennett, Joseph A. Clemas, Tom Wisniewski, Mary Struthers, Doris Cully, and Douglas J. MacNeil
- Subjects
Male ,Aldosterone synthase ,medicine.medical_specialty ,Pyridines ,Stereochemistry ,Clinical Biochemistry ,Pharmaceutical Science ,01 natural sciences ,Biochemistry ,Structure-Activity Relationship ,Cricetulus ,Internal medicine ,Drug Discovery ,medicine ,Animals ,Cytochrome P-450 CYP11B2 ,Humans ,Rats, Wistar ,Molecular Biology ,biology ,010405 organic chemistry ,Chemistry ,Organic Chemistry ,Imidazoles ,Macaca mulatta ,humanities ,0104 chemical sciences ,010404 medicinal & biomolecular chemistry ,Endocrinology ,Microsomes, Liver ,biology.protein ,Steroid 11-beta-Hydroxylase ,Molecular Medicine - Abstract
This invention relates to triazolopyridyl compounds of the structural formula: [Formula should be inserted here] or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.
- Published
- 2017